Citation Information :
Gupta ML, Yadav SS. Treatment of Isoniazid-resistant Tuberculosis: Need to Revisit. Indian J Chest Dis Allied Sci 2023; 65 (2):83-84.
Global Tuberculosis Programme. WHO operational handbook on tuberculosis: Module 4: Treatment: Drug-susceptible tuberculosis treatment. Available from: https://www.who.int/publications-detail-redirect/9789240050761.
Global Tuberculosis Programme. WHO operational handbook on tuberculosis. Module 4: Treatment - Drug-resistant tuberculosis treatment, 2022 update. Available from: https://www.who.int/publications-detail-redirect/9789240065116.
Ministry of Health and Family Welfare Government of India. Report of the first national anti-tuberculosis drug resistance survey: India 2014–16, 2018;1–24. Available from: https://tbcindia.gov.in/showfile.php?lid=3315.
American Thoracic Society. Medical section of the American lung association: Treatment of tuberculosis and tuberculosis infection in adults and children. Am Rev Respir Dis 1986;134(2):355–363. DOI: 10.1164/arrd.1986.134.2.355.
Fox W. Whither short-course chemotherapy? Br J Dis Chest 1981;75(4):331–357. DOI: 10.1016/0007-0971(81)90022-x.
Kumar P, Balooni V, Sharma BK, et al. High degree of multi-drug resistance and hetero-resistance in pulmonary TB patients from Punjab state of India. Tuberculosis (Edinb) 2014;94(1):73–80. DOI: 10.1016/j.tube.2013.10.001.
Stagg HR, Bothamley GH, Davidson JA, et al. Fluoroquinolones and isoniazid-resistant tuberculosis: Implications for the 2018 WHO guidance. Eur Respir J 2019;54(4):1900982. DOI: 10.1183/13993003.00982-2019.
